Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 13/20 | 0.56 |
| ▸ | AURKA | O14965 | 4/20 | 0.56 |
| ▸ | PDE4A | P27815 | 6/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.54 |
| ▸ | METAP2 | P50579 | 1/20 | 0.52 |
| ▸ | METAP1 | P53582 | 1/20 | 0.52 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27878086 | 0.81 | PDE5A (0.56) | PDE5AAURKAPDE4APDE4BPDE4C | |
| SCHEMBL14115847 | 0.81 | PDE5A (0.68) | PDE5AAURKAPDE4APDE4BPDE4C | |
| SCHEMBL1284270 | 0.80 | AURKA (0.73) | PDE5AAURKAMETAP2METAP1PRMT5 | |
| Hydrochloric Acid SCHEMBL11776694 | 0.79 | AURKA (0.71) | PDE5AAURKAMETAP2METAP1PRMT5 | |
| SCHEMBL31599727 | 0.77 | NUDT1 (0.53) | PDE5AAURKAPDE4APDE4BPDE4C | |
| SCHEMBL14091543 | 0.76 | PDE5A (0.51) | PDE5AAURKAPDE4APDE4BPDE4C | |
| SCHEMBL1170747 | 0.75 | METAP1 (0.72) | PDE5AAURKAPDE4APDE4BPDE4C | |
| SCHEMBL16940832 | 0.73 | ALDH1A1 (0.65) | METAP2 | |
| SCHEMBL14090248 | 0.73 | PDE5A (0.68) | PDE5AAURKAPDE4APDE4BPDE4C | |
| SCHEMBL12834042 | 0.72 | PDE5A (0.60) | PDE5AAURKAPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629147-B2 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2014-01-14 | — | — | US | disclosed |
| US-8629147-B2 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2014-01-14 | — | — | US | disclosed |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | disclosed |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | LCK, MALT1, MYD88 | PDE5A 2213/4885AURKA 780/4885PDE4A 1469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.